Please login to the form below

Not currently logged in
Email:
Password:

Dyax withdraws its European application for hereditary angioedema treatment Kalbitor

US biotech unable to provide sufficient data to support its hereditary angioedema drug for EU approval

US biotech Dyax has withdrawn its European marketing authorisation application for its hereditary angioedema (HAE) drug Kalbitor (ecallantide).

The decision came after the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) indicated Dyax had not provided sufficient evidence to demonstrate a positive benefit-risk balance for Kalbitor.

Dyax said it would consider resubmitting Kalbitor to the EMA once the results of an ongoing bioequivalence study using a high-strength formulation of the drug become available.

Dyax said it will press on with marketing applications and regulatory approvals in other international territories, including Australia, the Middle East and Latin America.

The biotech has already won for Kalbitor in the US, where the drug is approved to treat acute attacks of (HAE) in patients aged 16 years and over.

15th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics